UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
612 EAST LAMAR BOULEVARD, SUITE 400
ARLINGTON, TEXAS 76011-4125

January 22, 2009

St. Vincent Healthcare
ATTN: Christopher K. Fitz
Radiation Safety Officer
P.O. Box 35200
Billings, Montana 59107-5200

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 75 to NRC License No. 25-07553-01 **removing Margaret Barnes, MD, and Walter Degnan, MD, as authorized users from this license as requested.** An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review the enclosed document carefully and be sure that you understand all conditions. You can contact me at 817-860-8189 if you have any questions about this license.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC in writing of any change in mailing address.

3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area;

   b. If you decide not to acquire or possess and use authorized material; or

   c. When no principal activities under the license have been conducted for a period of 24 months.

4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:

   a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;

c. The licensee's mailing address changes;

d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or

e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.

5. Request and obtain a license amendment before you:

a. Change Radiation Safety Officers;

b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;

c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or

d. Change the name or ownership of your organization.

6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy. The NRC Enforcement Policy is available on the following internet address: http://www.nrc.gov/reading-rm/doc-collections/enforcement/.

An electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. Additional information regarding medical uses of radioactive materials may be obtained on the NRC Web site at: http://www.nrc.gov/materials/miau/med-use-toolkit.html. This site also provides the updated Training and Experience NRC Form 313A series of forms and guidance, as well as information on the revised regulations for naturally-occurring and accelerator-produced radioactive materials (NARM).

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Thank you for your cooperation.

Sincerely,

/RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B

Docket: 030-02396
License: 25-07553-01
Control: 472018

Enclosure: As stated

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 75

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with E-mail dated November 13, 2008
1. St. Vincent Healthcare	3. License number 25-07553-01 is amended in its entirety to read as follows:
2. P.O. Box 35200 Billings, Montana 59107-5200	4. Expiration date April 30, 2015
	5. Docket No. 030-02396

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (3M Model Nos. 6500, 6501, 6502, 6503 and 6504; Bard Brachytherapy Model STM-1251; Theragenics Model 200; Best Medical International Model 81-01 Series and Model 2301; Amersham Health, Medi-Physics, Inc., Model 6711 Oncoseed™)	D. 1,500 millicuries
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged kits	E. 10 millicuries
F. Iodine-125 permitted by 10 CFR 35.1000	F. Liquid as Proxima Therapeutics, Inc., Iotrex™	F. 5 curies
G. Strontium-90 permitted by 10 CFR 35.400	G. Sealed source (Amersham Corporation Model SIA.20)	G. 90 millicuries

9. Authorized use:

A. Any uptake, dilution, and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any use permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 75

E. In vitro studies.
F. For brachytherapy use in the Proxima Therapeutics' GliaSite® Radiation Therapy System permitted by 10 CFR 35.1000.
G. For ophthalmic radiation therapy permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facility located at:

A. 1233 North 30th Street, Billings, Montana, for material listed in Items 6.A. through 6.G.
B. 2900 12th Avenue North, Billings, Montana, for material listed in Items 6.A. and 6.B. only, and
C. Yellowstone Surgery Center, 1144 North 28th Street, Billings, Montana, for material listed in 6.D. only.

11. The Radiation Safety Officer for this license is Christopher K. Fitz.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use:

Authorized Users	Material and Use
Joseph C. Apostol, M.D.	35.200
Michael W. Brennan, M.D.	35.200
Paul LaVeau, M.D.	35.200
James K. Vincent, M.D.	35.200
Mitchell E. Gallagher, M.D.	35.100; 35.200; 31.11
Joseph P. Dillard, M.D.	35.100; 35.200; 31.11
Ann Giuliano, M.D.	35.100; 35.200; 35.300; 31.11
Robert Rex Dietz, M.D.	35.100; 35.200; 35.300
Kathleen A. Ryan, M.D.	35.100; 35.200; 35.300
John M. Schallenkamp, M.D.	35.400
John V. Hanson, M.D.	35.100; 35.200; 31.11; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
John S. Brandon, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
John Gerard Terry, M.D.	35.300; 35.400; Sr-90 for ophthalmic radiation therapy; 35.1000 only for Iodine-125 Iotrex™ in Proxima Therapeutics' GliaSite® Radiation Therapy System

C. The following individuals are authorized users for non-medical uses only:

Authorized Users	Material and Use
Hoyle Setzer, M.D.	31.11

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 75

D. The following individuals are authorized medical physicists:

Authorized Medical Physicists	Material and Use
Rodney J. Wimmer, Ph.D.	Sr-90 in an ophthalmic applicator for activity calculation
David W. Switzer, M.S.	Sr-90 in an ophthalmic applicator for activity calculation

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
25-07553-01

Docket or Reference Number
030-02396

Amendment No. 75

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated October 21, 2004 (ML063180067)
    B. Letter dated November 23, 2004 (ML043280649)
    C. Letter dated April 18, 2005 (ML051150232)
    D. Facsimile dated April 22, 2005 (ML051150214)
    E. Facsimile dated October 17, 2006 (ML062920135)
    F. Letter dated November 27, 2006 (ML063380384)
    G. E-mail dated December 4, 2006 (ML063380368 and ML063380384)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: January 22, 2009

By: _____
Roberto J. Torres, Senior Health Physicist
Nuclear Materials Safety Branch B
Region IV
Arlington, Texas 76011